The Company’s existing financial guidance remains unchanged, with the acquisition supporting OXB’s long-term top-line growth outlook and existing near and medium-term financial guidance. The Company expects to deliver above-market growth, achieve EBITDA profitability from FY 2025, and strengthen its competitive position in the global viral vector market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OXBDF:
- Oxford BioMedica Expands US Operations with Key Acquisition
- Oxford Biomedica price target raised to 970 GBp from 930 GBp at RBC Capital
- Oxford Biomedica Reports Strong Revenue Growth in 2025
- Oxford BioMedica Reports Robust H1 2025 Results, Strengthens Market Position
- Oxford Biomedica Announces Total Voting Rights Update